Survodutide

Boehringer Ingelheim drug slashes liver and belly fat

In Phase 3 trials, Boehringer Ingelheim's experimental obesity drug, survodutide, helped recipients shed up to 17% of their body weight over 76 weeks, crucially preserving muscle mass.